Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial
Visualitza/
Impacte
Scholar |
Altres documents de l'autoria: Núñez, Julio; Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar-Bonet, Luis; Lopez-Lereu, Maria Pilar; Monmeneu Menadas, Jose Vicente; Amiguet Comins, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; De la Espriella, Rafael; Lupón, Josep; Navarro, Jorge; Górriz, José Luis; Sanchis, Juan
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON TrialAutoria
Data de publicació
2020-02-13Editor
American Heart AssociationCita bibliogràfica
NÚÑEZ, Julio, et al. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial. Journal of the American Heart Association, 2020, vol. 9, no 4, p. e014254.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.ahajournals.org/doi/full/10.1161/JAHA.119.014254Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Background
Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. ... [+]
Background
Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance.
Methods and Results
Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were evaluated before and 7 and 30 days after randomization using linear mixed regression analysis. Results are presented as least‐square means with 95% CI. The primary end point was the change in T2* and T1 mapping at 7 and 30 days. Median age was 73 (65–78) years, with N‐terminal pro‐B‐type natriuretic peptide, ferritin, and transferrin saturation medians of 1690 pg/mL (1010–2828), 63 ng/mL (22–114), and 15.7% (11.0–19.2), respectively. Baseline T2* and T1 mapping values did not significantly differ across treatment arms. On day 7, both T2* and T1 mapping (ms) were significantly lower in the FCM arm (36.6 [34.6–38.7] versus 40 [38–42.1], P=0.025; 1061 [1051–1072] versus 1085 [1074–1095], P=0.001, respectively). A similar reduction was found at 30 days for T2* (36.3 [34.1–38.5] versus 41.1 [38.9–43.4], P=0.003), but not for T1 mapping (1075 [1065–1085] versus 1079 [1069–1089], P=0.577).
Conclusions
In patients with heart failure and iron deficiency, FCM administration was associated with changes in the T2* and T1 mapping cardiac magnetic resonance sequences, indicative of myocardial iron repletion. [-]
Proyecto de investigación
Vifor Pharma, CIBER Cardiovascular (grant numbers 16/11/00420 and 16/11/00403) ;Proyectos de Investigación de la Sección de Insuficiencia Cardiaca 2017 from Sociedad Española de Cardiología.Drets d'accés
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- MED_Articles [673]
Els següents fitxers sobre la llicència estan associats a aquest element:
Except where otherwise noted, this item's license is described as ª 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made